For research use only. Not for therapeutic Use.
PIP-199 is a selective inhibitor of RMI (RecQ-mediated genome instability protein) core complex/MM2 interaction, with an IC50 of 36 μM. PIP-199 can be used for the research of sensitizing resistant tumors to DNA crosslinking chemotherapeutics[1].
MM2 is the binding site of RMI complex on Fanconi anemia complementation group M protein (FANCM)[1].
Induction of the Fanconi anemia (FA) DNA repair pathway is a common mechanism by which tumors evolve resistance to DNA crosslinking chemotherapies[1].
Proper execution of the FA pathway requires interaction between the FANCM and the RMI complex, and mutations that disrupt FANCM/RMI interactions sensitize cells to DNA crosslinking agents[1].
| Catalog Number | I034777 |
| CAS Number | 622795-76-0 |
| Synonyms | ethyl 4-[(1-hydroxy-2-phenylindol-3-yl)-pyridin-2-ylmethyl]piperazine-1-carboxylate |
| Molecular Formula | C27H28N4O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H28N4O3/c1-2-34-27(32)30-18-16-29(17-19-30)26(22-13-8-9-15-28-22)24-21-12-6-7-14-23(21)31(33)25(24)20-10-4-3-5-11-20/h3-15,26,33H,2,16-19H2,1H3 |
| InChIKey | ROTCTSYSZSYNHB-UHFFFAOYSA-N |
| SMILES | CCOC(=O)N1CCN(CC1)C(C2=CC=CC=N2)C3=C(N(C4=CC=CC=C43)O)C5=CC=CC=C5 |
| Reference | [1]. Andrew F. Voter, et al. A high throughput screening strategy to identify protein-protein interaction inhibitors that block the Fanconi anemia DNA repair pathway. J Biomol Screen. 2016 Jul; 21(6): 626–633. |
